References
- Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100. https://doi.org/10.1016/S0140-6736(00)03540-6
- Spielmann L, Messer L, Moreau P, et al. Gemcitabine-induced myopathy. Semin Arthritis Rheum 2014;43:784-791. https://doi.org/10.1016/j.semarthrit.2013.11.009
- Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010;15:1227-1237. https://doi.org/10.1634/theoncologist.2009-0090
- Pentsova E, Liu A, Rosenblum M, O'Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol 2012;106:15-21. https://doi.org/10.1007/s11060-011-0672-8
- Ma L, Francia G, Viloria-Petit A, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005;65:5365-5373. https://doi.org/10.1158/0008-5472.CAN-04-3156
Cited by
- Gemcitabine : Myositis: case report vol.1672, pp.1, 2017, https://doi.org/10.1007/s40278-017-36932-z